Weekly Rundown: Key Catalysts for Small-Cap Stocks (January 5–9)

From recent disclosures to corporate developments, we’ve highlighted the top small-cap catalysts to watch. Now, as markets step into the first full week of 2026, a fresh batch of strategic updates and data-driven milestones are beginning to set the tone for the quarter. Below is your catalyst rundown for the week ahead (January 5–9).

--

CES 2026: Spotlight on Innovation, AI, and Small-Cap Participation

CES 2026, the world’s largest and most influential technology trade show, returns to Las Vegas from January 6–9, with press events and product launches kicking off as early as January 3–4. Produced by the Consumer Technology Association (CTA), CES attracts over 100,000 industry professionals, investors, media, and decision-makers from across the globe. This year’s event is expected to be dominated by artificial intelligence, with a strong emphasis on on-device AI, robotics, digital health, smart home automation, advanced mobility, and next-generation computing. CES 2026 will offer a first look at cutting-edge platforms, strategic partnerships, and product roadmaps that are likely to influence tech trends throughout the year. Several small- and micro-cap companies will also be participating, using CES as a high-visibility platform to showcase emerging technologies and attract partnership and investor interest.

Small-Cap Companies Participating: PERF, RDZN, LIDR, PMEC, RVSN, VLN WLDS, RR, BMR, CNVS, LUCY, ARAI ARBE, BB, DVLT, INVZ, FCUV

Other Companies with Material Events This Week:

• UPXI announced that the company will ring the Nasdaq Closing Bell at the Nasdaq MarketSite in Times Square, New York, on Monday, January 5, 2026. The ceremony will be led by CEO Allan Marshall and will include key members of the leadership team, Board of Directors, employees, and stakeholders. The event marks a milestone moment for the company, celebrating Upexi’s evolution and growth in recent years.

• CATX announced that updated data from its [212Pb]VMT-α-NET program has been accepted for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (ASCO-GI). The congress will take place from January 8–10, 2026, in San Francisco, California. The program focuses on targeted alpha radiotherapy for neuroendocrine tumors.

• JUNS is inviting investors to attend a live webinar on January 6, 2026, at 4:15 p.m. ET, hosted by RedChip. Jupiter Neurosciences’ Chairman and CEO Chister Rosén will provide an in-depth overview of the company’s platform, including the clinical path for its lead drug candidate, JOTROL™, which is advancing into a Phase 2a study for Parkinson’s disease. He will also discuss broader applications across neuroinflammatory and rare diseases, the launch of the Nugevia™ longevity line, and recent financing initiatives designed to support the company’s dual-path strategy into both pharmaceutical and consumer health markets.

• GANX will host a virtual Key Opinion Leader (KOL) event titled "Understanding GCase Substrates in Parkinson's Disease: Perspectives on Biomarkers and Disease Modification," on Tuesday, January 6, 2026, at 10:00 a.m. ET. The session will include clinical insights from Dr. Roy Alcalay (Tel Aviv Sourasky Medical Center) and Dr. Peter Lansbury (Harvard), and will spotlight new biomarker data from the Phase 1b clinical study of GT-02287, a candidate targeting Parkinson’s disease in GBA1 mutation carriers.

• DVLT announced plans to declare a special dividend consisting of warrants to purchase shares of Datavault AI common stock, with a record date of January 7, 2026. The company anticipates issuing one (1) warrant for every sixty (60) shares held, exercisable at $5.00 per share, with a one-year expiration. Notably, warrant holders must possess at least one Dream Bowl Meme Coin II token in a digital wallet to exercise. Terms will be finalized in a warrant agreement expected to be filed with the SEC. Separately, Datavault also unveiled enhancements to the 2026 Dream Bowl, scheduled for January 11, 2026, at AT&T Stadium. The event will include the world’s first tokenized autograph session, featuring 30 NFL players and a blockchain-secured memorabilia experience developed in partnership with Notable Live and PROVA SmartTag™, co-founded by Emmitt Smith.

• BDN declared a quarterly dividend of $0.08 per share, payable on January 22, 2026, to shareholders of record as of January 7, 2026, representing an annual rate of $0.32 per share.

• HUYA announced that Goose Goose Duck Mobile, co-published with Kingsoft Shiyou, will enter open beta in the Chinese market on January 7, 2026. The mobile game launch marks a key milestone in HUYA’s expansion into game publishing and monetizing its streaming ecosystem more directly.

• PAPL will host a virtual fireside chat on January 8, 2026, at 11:00 a.m. ET, featuring CEO Shubha Dasgupta and members of the Injective Foundation. The conversation will spotlight Pineapple’s continued blockchain integration, tokenization milestones, and digital asset treasury strategies as it aims to scale new infrastructure solutions in the fintech space.

• AMIX will present a poster at ASCO-GI 2026, taking place in San Francisco from January 8–10, 2026. The abstract, titled “Pain mitigation in pancreatic adenocarcinoma: A long-term analysis of denervation via transvascular RF energy-based ablation”, will be presented by Dr. Robert S. Schwartz, the company’s Chief Medical Officer. The poster will be part of Poster Session B on January 9.

• BFRG announced that a collaborative abstract with Eleison Pharmaceuticals has been accepted for presentation at ASCO-GI 2026. The poster, titled “Data-driven subtyping and differential glufosfamide benefit in pancreatic adenocarcinoma”, will appear in Poster Session B on January 9, and will also be published in the Journal of Clinical Oncology supplement.

• AIM declared a stock dividend of one share per 1,000 shares held, with a record date of January 9, 2026, and a distribution date of January 13, 2026. Fractional shares will be rounded down and settled in cash based on a share price of $1.305. The dividend applies to common stockholders and holders of eligible options/warrants.

• RNXT announced that its abstract has been accepted for presentation at ASCO-GI 2026. The data come from a sub-study of the ongoing TIGeR-PaC Phase III trial, comparing intra-arterial versus intravenous gemcitabine in locally advanced pancreatic cancer. The presentation will take place on January 9, 2026, during two poster sessions.

• RVPH CEO Dr. Laxminarayan Bhat will present at the Sachs 9th Annual Neuroscience Innovation Forum on January 11, 2026, at 1:20 p.m. PT, hosted at the Marines’ Memorial Club in San Francisco. The presentation will highlight Reviva’s CNS pipeline and recent developments.

• DRTS > Alpha Tau Medical announced that two abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place January 8–10, 2026, in San Francisco, California. The abstracts, titled “Feasibility, Safety and Efficacy of Endoscopic Ultrasound-Guided Alpha Radiotherapy for Advanced Pancreatic Cancer: A Pilot Study” and “Inflammatory and Immune Marker Dynamics following Intratumoral Alpha DaRT for Pancreatic Cancer”, will be presented by trial investigators Dr. Corey Miller and Dr. Kim Anh Ma based on data from the company’s completed pilot study in Montreal, Canada.

• GPUS will begin issuing regular investor updates starting in January 2026. These include weekly Bitcoin Treasury updates (Tuesdays), bi-weekly Michigan AI Data Center progress reports (every other Thursday), and monthly estimated total/net assets per share (first Wednesday of each month). These updates aim to provide consistent insight into treasury strategy and infrastructure developments.

• ASBP submitted a Pre-IND meeting package to the FDA for its high-dose sublingual aspirin product for suspected acute myocardial infarction (AMI). The FDA responded positively, stating it would issue written guidance by January 2, 2026, in lieu of a formal meeting. The milestone supports the company’s broader regulatory and clinical development goals.

• SXTP RedChip Investor Webinar with 60 Degrees Pharmaceuticals will be held on January 8 at 4:15 PM ET. The event will feature a brief presentation from executive leadership followed by live Q&A. Discussion topics are expected to include tafenoquine development for babesiosis and its regulatory path forward, commercial progress for ARAKODA®, and key milestones planned for 2026, including upcoming FDA interactions.

--

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.